Europe and Rest of the World ("ROW") Generic Sales
Sales of European and ROW generic products were $217 million in the second
quarter of 2008, compared to $188 million in the prior year period. This
increase is primarily related to the positive impact of foreign currency
exchange fluctuations compared to the prior year period. Excluding the
impact of foreign currency fluctuations, overall sales were in line with
last year as strong growth in Russia and other Central European markets
offset declines in Croatia and Germany.
Proprietary Product Sales
The Company's proprietary product sales were $118 million for the second quarter of 2008, compared to $102 million in the prior year period. For the first six months of 2008, proprietary product sales were $214 million, compared to $191 million in the prior year period. The increase in proprietary sales for the quarter and the six month period was primarily attributable to increased sales of several products, including SEASONIQUE(R) extended-cycle oral contraceptive and the PARAGARD(R) IUC.
Alliance and Development Revenue
During the second quarter of 2008, the Company reported alliance and development revenue of $93 million, up from $36 million in the prior year period. For the first six months of 2008, alliance and development revenue was $125 million, compared to $61 million in the prior year period. The increase in the quarter and the six month period is primarily related to the $53 million payment made by Allergan to Barr in May 2008 related to Allergan's buy-out of all future financial obligations related to the Sanctura(R) product that PLIVA divested in 2005 to Esprit Pharma, which has since been acquired by Allergan.
Other revenue primarily includes revenue from the Company's non-core
operations, including the diagnostic, disinfectants, dialysis and infusions
(DDD&I) business. Other revenue totaled $11
|SOURCE Barr Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved